We design ground-breaking therapies through precision-targeting of membrane receptors to bring hope to people living with autoimmune diseases. Dedicated to the development of next generation therapies to treat inflammatory autoimmune diseases, our company was launched in 2020 with investments from CTI Life Sciences, adMare BioInnovations, Domain Therapeutics, and an exclusive global license from Strasbourg University on a technology and related know-how initially developed by Dr. Dominique Bagnard.
